Systemic Leukocyte-Directed siRNA Delivery Revealing Cyclin D1 as an Anti-Inflammatory Target

Cyclin D1 (CyD1) is a pivotal cell cycle–regulatory molecule and a well-studied therapeutic target for cancer. Although CyD1 is also strongly up-regulated at sites of inflammation, its exact roles in this context remain uncharacterized. To address this question, we developed a strategy for selectively silencing CyD1 in leukocytes in vivo. Targeted stabilized nanoparticles (tsNPs) were loaded with CyD1–small interfering RNA (siRNA). Antibodies to β7 integrin (β7 I) were then used to target specific leukocyte subsets involved in gut inflammation. Systemic application of β7 I-tsNPs silenced CyD1 in leukocytes and reversed experimentally induced colitis in mice by suppressing leukocyte proliferation and T helper cell 1 cytokine expression. This study reveals CyD1 to be a potential anti-inflammatory target, and suggests that the application of similar modes of targeting by siRNA may be feasible in other therapeutic settings.

[1]  E. Kuipers,et al.  Wnt pathway-related gene expression during malignant progression in ulcerative colitis. , 2007, Acta histochemica.

[2]  A. Ashworth,et al.  Utilizing RNA interference to enhance cancer drug discovery , 2007, Nature Reviews Drug Discovery.

[3]  Mark E. Davis,et al.  Administration in non-human primates of escalating intravenous doses of targeted nanoparticles containing ribonucleotide reductase subunit M2 siRNA , 2007, Proceedings of the National Academy of Sciences.

[4]  J. Lieberman,et al.  Selective gene silencing in activated leukocytes by targeting siRNAs to the integrin lymphocyte function-associated antigen-1 , 2007, Proceedings of the National Academy of Sciences.

[5]  Leaf Huang,et al.  Targeted delivery of antisense oligodeoxynucleotide and small interference RNA into lung cancer cells. , 2006, Molecular pharmaceutics.

[6]  Judy Lieberman,et al.  Running interference: prospects and obstacles to using small interfering RNAs as small molecule drugs. , 2006, Annual review of biomedical engineering.

[7]  A. Haegebarth,et al.  Differential Regulation of D-Type Cyclins in the Mouse Intestine , 2006, Cell cycle.

[8]  T. Ochiya,et al.  Efficient delivery of small interfering RNA to bone-metastatic tumors by using atelocollagen in vivo. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[9]  Keith Bowman,et al.  Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs , 2005, Nature Biotechnology.

[10]  Judy Lieberman,et al.  Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors , 2005, Nature Biotechnology.

[11]  Chenguang Wang,et al.  Minireview: Cyclin D1: normal and abnormal functions. , 2004, Endocrinology.

[12]  Matthias John,et al.  Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs , 2004, Nature.

[13]  R. Schiffelers,et al.  Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle. , 2004, Nucleic acids research.

[14]  F. Brennan,et al.  IL-10 Gene Therapy Is Therapeutic for Dextran Sodium Sulfate-Induced Murine Colitis , 2004, Digestive Diseases and Sciences.

[15]  C. Dass.  Lipoplex-mediated delivery of nucleic acids: factors affecting in vivo transfection , 2004, Journal of Molecular Medicine.

[16]  Dan Peer,et al.  Hyaluronan is a key component in cryoprotection and formulation of targeted unilamellar liposomes. , 2003, Biochimica et biophysica acta.

[17]  D. Stacey.  Cyclin D1 serves as a cell cycle regulatory switch in actively proliferating cells. , 2003, Current opinion in cell biology.

[18]  L. Huang,et al.  Protamine sulfate enhances lipid-mediated gene transfer , 1997, Gene Therapy.

[19]  M. Brenner,et al.  The β7 integrins in mucosal homing and retention , 1995 .

[20]  T. Yoshino,et al.  Distinct but overlapping epitopes are involved in alpha 4 beta 7-mediated adhesion to vascular cell adhesion molecule-1, mucosal addressin-1, fibronectin, and lymphocyte aggregation. , 1994, Journal of immunology.